The albumin-bilirubin (ALBI) score was initially validated to assess the outcome of patients with hepatocellular carcinoma (HCC), and its effectiveness has been confirmed by relevant studies [6–8]. The gene discussed is ALB; the disease is hepatocellular carcinoma.